Restless Legs Syndrome: Clinical Overview
Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a sleep-related sensorimotor disorder characterized by an urge to move the legs, usually accompanied by uncomfortable sensations, that begins or worsens during periods of rest, is relieved by movement, and occurs predominantly in the evening or night. Clinically significant RLS (symptoms ≥2x/week causing at least moderate distress) affects approximately 2–3% of adults and 0.5–1% of children. This article provides a comprehensive clinical overview of the diagnosis, pathophysiology, and management of RLS; for detailed treatment recommendations, see the companion article on the AASM 2025 Clinical Practice Guideline.
Bottom Line
- Diagnosis: RLS is a clinical diagnosis based on 5 IRLSSG essential criteria (2014) — no confirmatory test exists
- Pathophysiology: Brain iron deficiency is the central upstream mechanism, leading to dopaminergic dysfunction and adenosine receptor imbalance — this explains the circadian symptom pattern
- Iron status: All patients with clinically significant RLS should have serum ferritin and TSAT checked; supplement if ferritin ≤75 ng/mL or TSAT <20%
- First-line treatment: Alpha-2-delta ligands (gabapentin, pregabalin, gabapentin enacarbil) — dopamine agonists are no longer standard therapy due to augmentation risk
- Augmentation: Iatrogenic worsening on dopaminergic therapy affects 40–70% of patients long-term; earlier symptom onset, spread to arms, and greater intensity are hallmarks
- Medications that worsen RLS: SSRIs/SNRIs, mirtazapine, antihistamines, dopamine antagonists (metoclopramide, antipsychotics)
- PLMS: ~80% of RLS patients have periodic limb movements of sleep; PLMS index >15/h (adults) or >5/h (children) is abnormal
Epidemiology
| Parameter | Data |
|---|---|
| Overall prevalence (any RLS symptoms) | 5–15% of adults (varies by diagnostic criteria); ~7% globally (systematic review, JOGH 2024) |
| Clinically significant RLS | 2–3% of adults; 0.5–1% of children |
| Sex ratio | ~1.5–2x more common in women; partly related to parity (nulliparous women have same risk as men) |
| Age | Prevalence increases with age; mean onset before age 20 in ~40% of patients with early-onset RLS |
| Heritability | ~50% of patients have an affected first-degree relative; ~60% of early-onset RLS is familial |
| Pregnancy | ~26.5% prevalence in third trimester; typically resolves within months postpartum |
| ESRD/hemodialysis | ~24% prevalence; up to one-third of dialysis patients |
| Geographic variation | Highest in Europe and North America; lower in Asia (1–7%); more common in Northern European heritage |
Diagnostic Criteria (IRLSSG 2014)
RLS is a clinical diagnosis. The International RLS Study Group (IRLSSG) revised the diagnostic criteria in 2014 (Allen et al., Sleep Medicine 2014), unifying adult and pediatric criteria into a single framework. All five essential criteria must be met:
Five Essential Diagnostic Criteria
- An urge to move the legs, usually but not always accompanied by, or felt to be caused by, uncomfortable and unpleasant sensations in the legs
- The urge begins or worsens during periods of rest or inactivity, such as lying down or sitting
- The urge is partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues
- The urge occurs or is worse in the evening or night than during the day
- The above features are not solely accounted for as symptoms primary to another medical or behavioral condition (e.g., myalgia, venous stasis, leg edema, arthritis, leg cramps, positional discomfort, habitual foot tapping)
Clinical significance specifier: Symptoms cause distress or impairment in social, occupational, educational, or other important areas of functioning by their impact on sleep, energy, daily activities, behavior, cognition, or mood.
Course specifiers:
- Chronic-persistent: Symptoms ≥2x/week for the past year (when untreated)
- Intermittent: Symptoms <2x/week for the past year, with at least 5 lifetime events
Key 2014 update: The 5th criterion was added to improve specificity by requiring exclusion of RLS mimics. The 4th criterion was also modified — the circadian pattern may become less prominent in severe, long-standing disease.
Clinical Features
Sensory Symptoms
Patients use diverse and often unusual terms to describe the sensations: creeping, crawling, tingling, pulling, throbbing, burning, aching, itching, buzzing, or a "deep bone itch." Some describe it as "bugs crawling up the legs" or "fizzy soda bubbling through the veins." The sensation is often difficult for patients to articulate. In severe cases, it may be described as painful. Children frequently describe RLS sensations simply as "pain" or "hurts," contributing to misdiagnosis as growing pains.
Motor Component
The urge to move is the defining feature, not just sensory discomfort. Movement (walking, stretching, rubbing) provides temporary relief, but symptoms return with rest. Patients often develop habitual behaviors: pacing, rocking, hot baths, leg rubbing, or massage.
Body Distribution
- Legs: Most commonly affected (calves > thighs > feet); typically bilateral but may be asymmetric
- Arms: Involved in more severe or advanced disease, and especially with augmentation
- Trunk, chest, face: Rarely affected
- In contrast to peripheral neuropathy, RLS typically affects the calves rather than the toes/feet
Circadian Pattern
- Symptoms exclusively or predominantly in the evening and night
- Peak severity typically between 10 PM and 2 AM
- Minimal or absent in the morning
- Reflects the coordinated evening decline in dopamine, circadian variation in serum iron, and rise in melatonin
Sleep Impact
- Sleep-onset insomnia: ~90% of RLS patients report difficulty falling or staying asleep
- PLMS association: ~80% of RLS patients have periodic limb movements of sleep
- Sleep architecture changes: Decreased sleep efficiency, total sleep time, REM%, and N2%; increased sleep latency, WASO, N1%, arousal index, and REM latency
Pathophysiology
Brain Iron Deficiency
Brain iron deficiency (BID) is the central upstream mechanism. Iron is a critical cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. Key evidence:
- CSF ferritin is significantly lower in RLS patients than controls, even when peripheral (serum) iron is normal
- MRI: Decreased iron content in the substantia nigra
- Autopsy studies: Iron deficiency in the substantia nigra and myelin, with ~25% reduction in myelin-associated proteins — but no neurodegeneration (no loss of dopaminergic neurons or inclusion bodies)
- RLS prevalence in iron deficiency anemia: ~30% (vs. 5–7% in general population)
- Serum ferritin does not reliably reflect brain iron status (poor correlation with CSF ferritin in RLS)
Iron-Dopamine Connection
Iron deficiency in the substantia nigra leads to a presynaptic hyperdopaminergic state with compensatory D2 receptor downregulation. This postsynaptic adaptation is appropriate during daytime (when dopamine is higher) but overcompensates in the evening when dopamine levels naturally decline — producing the characteristic circadian symptom pattern.
Adenosine Hypothesis
Brain iron deficiency induces a hypoadenosinergic state through A1 adenosine receptor (A1R) downregulation in the cortex and striatum, with concomitant A2A receptor (A2AR) upregulation. This A1R/A2AR imbalance within cortico-striatal glutamatergic terminals favors excitatory neurotransmission, leading to cortical hyperexcitability, hyperarousal (insomnia), and periodic limb movements.
HIF Pathway
RLS brains show normoxic HIF (hypoxia-inducible factor) pathway activation despite no clinical hypoxia. Iron deficiency inhibits prolyl hydroxylase, preventing HIF-1α degradation. HIF-1α immunoreactivity is significantly increased in substantia nigra neurons; HIF-2α and VEGF are upregulated in cortical microvasculature. This may explain the association of RLS with altitude and pulmonary disease.
Genetics
| Gene | Function | Notes |
|---|---|---|
| MEIS1 | Neural development, brain iron regulation | Strongest genetic risk factor (OR 1.92); expression increases with iron chelation |
| BTBD9 | Brain iron regulation, dopamine signaling | Knockout mice exhibit RLS-like phenotype; modulates D2 receptor expression |
| MAP2K5 | Dopaminergic system | Risk variant in Caucasian and Asian populations |
| PTPRD | Synaptic adhesion | Expressed in striatum and spinal cord |
| TOX3 | Transcription factor | OR 1.1–1.9 for Caucasian risk variants |
| SKOR1 | Neuronal differentiation | Direct interaction with MEIS1 demonstrated |
At least 164 genetic polymorphisms have been identified through GWAS, but known variants explain less than 10% of overall heritability. Notably, testing of 111 iron metabolism genes found no significant associations — the genetic contribution is not through classical iron metabolism pathways.
Classification: Primary vs. Secondary RLS
| Type | Features |
|---|---|
| Primary (idiopathic) | No identifiable secondary cause; strong genetic component (~60% familial); earlier onset (<40 years) with slower progression; typically chronic |
| Secondary | Associated with an identifiable condition (see below); later onset; may resolve with treatment of the underlying cause |
Common Secondary Causes
| Cause | RLS Prevalence | Mechanism |
|---|---|---|
| Iron deficiency anemia | ~30% | Reduced brain iron; impaired tyrosine hydroxylase function |
| Pregnancy | ~26.5% (3rd trimester) | Iron depletion, folate changes, hormonal factors; resolves postpartum |
| ESRD / CKD (dialysis) | ~24% | Iron deficiency + uremic toxins + altered dopamine metabolism |
| Peripheral neuropathy | Variable | Small fiber neuropathy may coexist with or mimic RLS; both conditions can share underlying iron deficiency |
| Diabetes mellitus | Elevated | Partly via neuropathy and metabolic mechanisms |
| Spinal cord disease | Variable | Myelopathy, multiple sclerosis — disruption of descending dopaminergic pathways |
| Medications | Variable | See medications section below |
Medications That Worsen RLS
Commonly Prescribed Medications That Exacerbate RLS
Addressing medication-related exacerbation is the first step in RLS management (AASM Good Practice Statement). Offending medications should be reduced or replaced when clinically feasible.
| Drug Class | Examples | Risk Level | Mechanism |
|---|---|---|---|
| SSRIs | Sertraline, paroxetine, fluoxetine, escitalopram, citalopram | High | Serotonin inhibits dopaminergic neurotransmission; 2–10% treatment-emergent RLS |
| SNRIs | Venlafaxine, duloxetine | High | Similar mechanism to SSRIs |
| Mirtazapine | Mirtazapine | High (among the worst) | Serotonergic + antihistaminic properties; strong evidence for RLS induction/exacerbation |
| First-generation antihistamines | Diphenhydramine, hydroxyzine, doxylamine | High | Cross BBB; central dopamine receptor antagonism; commonly in OTC sleep aids |
| Dopamine antagonists (antiemetics) | Metoclopramide, prochlorperazine, promethazine | High | Central D2 receptor blockade |
| Antipsychotics | Typical antipsychotics; also quetiapine, risperidone, olanzapine | High | Dopamine receptor antagonism |
| TCAs | Amitriptyline | Moderate | Less well-studied; antihistaminic and serotonergic properties |
Safer Alternatives When an Antidepressant Is Needed
- Bupropion (first choice) — non-serotonergic (dopamine/norepinephrine reuptake inhibitor); may actually improve RLS symptoms
- Trazodone (second choice) — generally does not worsen PLMS; isolated case reports of RLS induction but much less common than SSRIs/mirtazapine
- Doxepin (low-dose) — sedating TCA that does not appear to aggravate PLMS
Differential Diagnosis
| Condition | Distinguishing Features from RLS |
|---|---|
| Akathisia (neuroleptic-induced) | Generalized inner restlessness (not limb-specific); stereotyped body movements (rocking, crossing legs); no preceding sensory discomfort; no circadian pattern; associated with antipsychotic/antiemetic use; movement does not reliably relieve symptoms |
| Peripheral neuropathy | Burning/painful sensations in distal extremities (toes, feet) rather than calves; no motor restlessness; no circadian pattern; not relieved by movement; abnormal neurological exam (decreased sensation, absent reflexes); no dopaminergic response. Can coexist with RLS |
| Nocturnal leg cramps | Unilateral, sudden painful involuntary contraction of a single muscle (typically calf); visible/palpable muscle hardening; relieved by dorsiflexion/stretching of the specific muscle; sharp pain easily distinguished from RLS discomfort |
| Vascular claudication | Occurs during activity (walking), relieved by rest (opposite of RLS); absent pedal pulses, cool extremities, skin changes; no circadian pattern |
| Positional discomfort | Localized to pressure points; no circadian pattern; relieved by position change (not ongoing movement); does not recur in the new position |
| Venous insufficiency | Leg heaviness/aching with prolonged standing; skin changes (stasis dermatitis, varicosities); worsens with standing (not rest); no circadian pattern |
| Growing pains (children) | 45% of children describe RLS as "pain/hurts" making this a common misdiagnosis; growing pains involve throbbing in thighs/calves; not relieved by movement but by massage, cold, and analgesics; may represent early RLS in some cases |
| Painful legs / moving toes | Continuous pain (not just at rest); involuntary toe movements at rest and during sleep; no circadian pattern; no relief from voluntary movement |
Assessment Tools
IRLS Severity Scale
The International RLS Study Group Rating Scale (IRLS) is the most widely used and validated severity instrument. It is a 10-question clinician-administered scale assessing symptom intensity, frequency, sleep impact, mood impact, and functional impairment. Each question is scored 0–4.
| Score | Severity |
|---|---|
| 1–10 | Mild |
| 11–20 | Moderate |
| 21–30 | Severe |
| 31–40 | Very Severe |
Minimal clinically important difference (MCID): 3 points. A self-administered version (sIRLS) is also validated.
Other Assessment Methods
- Suggested Immobilization Test (SIT): Patient sits in bed with legs outstretched for 60 minutes; measures both sensory symptoms (patient ratings every 5–10 minutes) and periodic limb movements during wakefulness (PLMW). SIT index >40 correctly identifies RLS in 81% of patients. A multiple SIT (m-SIT) with 7 sessions every 2 hours from noon to midnight validates the circadian pattern.
- Polysomnography: Not required for diagnosis but useful for confirming PLMS. PLMS index >15/h in adults (>5/h in children) is abnormal. AASM scoring: anterior tibialis EMG increase >8 μV above rest, duration 0.5–10 seconds, ≥4 movements in series, 5–90 seconds apart.
Periodic Limb Movements of Sleep (PLMS)
- ~80% of RLS patients have PLMS on polysomnography
- Stereotyped dorsiflexion of the foot (sometimes with knee/hip flexion), occurring roughly every 15–30 seconds
- Particularly during the first 4 hours of the sleep period, with high night-to-night variability
- Associated with EEG arousals and invariably with elevations in heart rate and blood pressure
- PLMD is diagnosed when PLMS are frequent (>15/h adults, >5/h children), there is coexisting clinically significant sleep disturbance or daytime dysfunction, and other sleep disorders associated with PLMS (RLS, untreated OSA, RBD, narcolepsy) are absent
- PLMS can occur without RLS, and RLS diagnosis does not require PLMS documentation
Augmentation
Augmentation: The Most Important Long-Term Complication
Augmentation is the iatrogenic worsening of RLS symptoms caused by dopaminergic treatment. It is not tolerance (which involves a reduced response to the same dose) and not disease progression. National data from 2017–2018 showed that 60% of medication-treated RLS patients were still prescribed dopamine agonists, often at doses exceeding FDA recommendations.
Diagnostic Criteria (IRLSSG/MDS, Garcia-Borreguero et al. 2016)
Prerequisite: Previous positive treatment response to dopaminergic medication.
Required: Criterion A + B, or A + C, or A + B + C:
- Criterion A (Basic): Increase in symptom severity on 5 of 7 days during the previous week, with no other explanation
- Criterion B (Paradoxical response): Symptoms sometimes increase after a dose increase AND sometimes improve after a dose decrease
- Criterion C (Earlier onset + associated features): Earlier symptom onset by ≥4 hours, or earlier onset by 2–4 hours plus at least one of: shorter latency at rest, spread to other body parts, greater intensity, or shorter medication effectiveness
Clinical Features of Augmentation
- Earlier daily symptom onset (the hallmark) — symptoms begin in the afternoon instead of evening
- Shorter latency at rest — symptoms appear more quickly when sitting/lying
- Spread to upper limbs (arms, sometimes trunk)
- Greater intensity of sensory symptoms and motor urge
- Shorter duration of medication relief (wearing off more quickly)
- Paradoxical dose-response — increasing the dose temporarily helps but ultimately worsens symptoms
Augmentation Rates by Drug Class
| Drug | Augmentation Rate | Onset |
|---|---|---|
| Levodopa | 40–80% | Earliest and most frequent; months |
| Pramipexole / Ropinirole | 40–70% (10-year cumulative); ~8%/year | Average onset ~2.7 years of continuous therapy |
| Rotigotine (transdermal) | ~36% after 5 years | Slightly lower, possibly due to continuous delivery |
| Alpha-2-delta ligands | Very rare / none reported | Not a true augmentation phenomenon |
Risk Factors for Augmentation
- Higher dopaminergic doses (>0.5 mg/day pramipexole; >4 mg/day ropinirole)
- Levodopa use (highest risk agent)
- Low serum ferritin (<50 μg/L)
- Longer disease duration and higher baseline IRLS severity
- Evening or multiple daily dosing
Augmentation Management Algorithm
- Confirm augmentation (vs. natural progression, inadequate dosing, iron deficiency, new medication effect)
- Optimize iron status: Check ferritin and TSAT; supplement if ferritin <75 μg/L
- Gradual taper of dopamine agonist over 2–4 weeks (expect severe withdrawal: worsened RLS, insomnia, mood changes, muscle spasms, sweats, malaise lasting 1–6 weeks)
- Initiate alternative therapy: Alpha-2-delta ligand (gabapentin, pregabalin, gabapentin enacarbil); low-dose opioid (oxycodone, methadone, buprenorphine) to bridge the withdrawal period
- Monitor: Resolution of daytime symptoms expected; follow-up IRLS scoring
Treatment Overview
For detailed pharmacological recommendations and evidence grading, see the companion article: AASM Clinical Practice Guideline (2025). The following summarizes the current treatment paradigm.
Step 1: Address Exacerbating Factors
- Review and discontinue/replace offending medications (SSRIs, antihistamines, dopamine antagonists)
- Reduce alcohol, caffeine, nicotine (especially in the evening)
- Treat untreated obstructive sleep apnea
Step 2: Iron Optimization
| Iron Status | Intervention |
|---|---|
| Ferritin ≤75 ng/mL or TSAT <20% | Oral iron (ferrous sulfate 325 mg with vitamin C, on empty stomach, every other day) or IV iron (ferric carboxymaltose preferred) |
| Ferritin 75–100 ng/mL | IV iron only (oral iron poorly absorbed at ferritin >50–75) |
| ESRD: ferritin <200 ng/mL, TSAT <20% | IV iron sucrose |
| Children: ferritin <50 ng/mL | Oral ferrous sulfate |
Iron studies should be drawn in the morning after avoiding iron-containing supplements and foods for 24 hours.
Step 3: First-Line Pharmacotherapy
- Alpha-2-delta ligands (strong recommendation, AASM 2025): gabapentin, gabapentin enacarbil, or pregabalin
- Gabapentin enacarbil is the only FDA-approved drug for RLS recommended by the 2025 AASM CPG
- Common side effects: somnolence, dizziness
Step 4: Second-Line Options
- Dipyridamole (conditional recommendation) — increases extracellular adenosine; biologic rationale in brain-iron deficiency
- Bilateral peroneal nerve stimulation (conditional recommendation) — noninvasive wearable device
Step 5: Refractory RLS
- Low-dose opioids (conditional recommendation): extended-release oxycodone, methadone, buprenorphine
- Requires appropriate screening and monitoring for abuse risk
Dopamine Agonists: Limited Role
- Now recommended against standard use (conditional, AASM 2025) due to augmentation risk
- May be considered for: short-term use (e.g., travel), poor tolerability of other options, or patient preference with understanding of augmentation risk
- If used: keep dose as low as possible; maintain ferritin >75 ng/mL; monitor for augmentation and impulse control disorders at every visit
Non-Pharmacological Management
- Exercise: Moderate-intensity aerobic exercise 3–5x/week reduces symptom severity (walking, cycling, swimming); very vigorous exercise may worsen RLS
- Sleep hygiene: Regular sleep-wake schedule; avoidance of caffeine, alcohol, nicotine in evening
- Pneumatic compression: RCT demonstrated clinically significant improvement; complete relief in one-third of subjects
- Counter-stimulation: Hot or cold baths, leg massage, compressive foot wraps
- Movement breaks: Plan for long flights, car rides, or periods of prolonged sitting
Comorbidities
| Comorbidity | Association | Notes |
|---|---|---|
| Cardiovascular disease | Hypertension HR 1.19; CHD and stroke risk elevated in some cohorts | Mechanisms: chronic sleep disruption, autonomic dysregulation, systemic inflammation; evidence is mixed after controlling for confounders |
| Depression / Anxiety | RLS prevalence ~43% in depression, ~50% in anxiety | Bidirectional relationship; treatment dilemma since antidepressants (SSRIs) can worsen RLS |
| ADHD (children) | Up to 44% of children with ADHD have RLS; 26% of children with RLS have ADHD | Shared dopaminergic dysfunction and iron deficiency; sleep disruption causes daytime inattention and hyperactivity |
| Migraine | RLS prevalence ~19% in migraine; OR 1.5–2.0 | Shared dopaminergic and iron metabolism pathways |
| Insomnia | ~90% of moderate-severe RLS | Primary morbidity of RLS; both sleep-onset and sleep-maintenance insomnia |
Special Populations
Pregnancy
- Prevalence ~26.5% in third trimester; typically resolves within months postpartum
- Related to iron and folate depletion, hormonal changes
- Treatment: iron supplementation first-line; consider pregnancy-specific safety profile for all medications
- Most pharmacological treatments lack adequate safety data in pregnancy
Children
- Diagnosis can be challenging — children may describe sensations as "pain" or "hurts"
- Ferrous sulfate is the only recommended treatment (conditional, ferritin <50 ng/mL)
- No evidence supports treating children with medications commonly used in adults
- Monitor symptoms, QoL, sleep quality, and academic performance
- Screen for ADHD given the high comorbidity rate
ESRD / Dialysis
- Gabapentin (dose-adjusted for renal function) — conditional recommendation
- IV iron sucrose (ferritin <200 ng/mL, TSAT <20%) — conditional recommendation
- Vitamin C — conditional recommendation (clinically significant improvement, low certainty)
- Levodopa and rotigotine — conditional against (augmentation risk)
References
- Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria. Sleep Med. 2014;15(8):860–873.
- Winkelman JW, Berkowski JA, DelRosso LM, et al. Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2025;21(1):137–152.
- Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS Foundation. Sleep Med. 2016;21:1–11.
- Trenkwalder C, Allen R, Högl B, et al. Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol. 2018;17(11):994–1005.
- Ferré S, Earley CJ, Gulyani S, et al. In search of an adenosinergic/dopaminergic mechanism for the neurobiology of restless legs syndrome. Prog Neurobiol. 2022;216:102318.